Logo image of AVBP

ARRIVENT BIOPHARMA INC (AVBP) Stock Price, Quote, News and Overview

NASDAQ:AVBP - Nasdaq - US04272N1028 - Common Stock - Currency: USD

23.57  +0.05 (+0.21%)

AVBP Quote, Performance and Key Statistics

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (6/9/2025, 2:46:54 PM)

23.57

+0.05 (+0.21%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High36.37
52 Week Low15.47
Market Cap806.33M
Shares34.21M
Float27.85M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-13 2025-08-13
IPO01-26 2024-01-26


AVBP short term performance overview.The bars show the price performance of AVBP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

AVBP long term performance overview.The bars show the price performance of AVBP in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of AVBP is 23.57 USD. In the past month the price increased by 19.09%. In the past year, price increased by 26.79%.

ARRIVENT BIOPHARMA INC / AVBP Daily stock chart

AVBP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.47 335.10B
AMGN AMGEN INC 14.04 156.70B
GILD GILEAD SCIENCES INC 14.58 140.40B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.02B
REGN REGENERON PHARMACEUTICALS 11.58 55.42B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.62B
ARGX ARGENX SE - ADR 101.61 35.68B
ONC BEONE MEDICINES LTD-ADR 6.77 28.62B
BNTX BIONTECH SE-ADR N/A 26.15B
NTRA NATERA INC N/A 22.54B
BIIB BIOGEN INC 8.52 19.75B
SMMT SUMMIT THERAPEUTICS INC N/A 16.11B

About AVBP

Company Profile

AVBP logo image Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Newtown Square, Pennsylvania and currently employs 52 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.

Company Info

ARRIVENT BIOPHARMA INC

18 Campus Blvd., Suite 100

Newtown Square PENNSYLVANIA US

Employees: 40

AVBP Company Website

Phone: 12407806356

ARRIVENT BIOPHARMA INC / AVBP FAQ

What is the stock price of ARRIVENT BIOPHARMA INC today?

The current stock price of AVBP is 23.57 USD. The price increased by 0.21% in the last trading session.


What is the ticker symbol for ARRIVENT BIOPHARMA INC stock?

The exchange symbol of ARRIVENT BIOPHARMA INC is AVBP and it is listed on the Nasdaq exchange.


On which exchange is AVBP stock listed?

AVBP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARRIVENT BIOPHARMA INC stock?

14 analysts have analysed AVBP and the average price target is 40.29 USD. This implies a price increase of 70.94% is expected in the next year compared to the current price of 23.57. Check the ARRIVENT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARRIVENT BIOPHARMA INC worth?

ARRIVENT BIOPHARMA INC (AVBP) has a market capitalization of 806.33M USD. This makes AVBP a Small Cap stock.


How many employees does ARRIVENT BIOPHARMA INC have?

ARRIVENT BIOPHARMA INC (AVBP) currently has 40 employees.


What are the support and resistance levels for ARRIVENT BIOPHARMA INC (AVBP) stock?

ARRIVENT BIOPHARMA INC (AVBP) has a support level at 21.25 and a resistance level at 23.53. Check the full technical report for a detailed analysis of AVBP support and resistance levels.


Should I buy ARRIVENT BIOPHARMA INC (AVBP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARRIVENT BIOPHARMA INC (AVBP) stock pay dividends?

AVBP does not pay a dividend.


When does ARRIVENT BIOPHARMA INC (AVBP) report earnings?

ARRIVENT BIOPHARMA INC (AVBP) will report earnings on 2025-08-13.


What is the Price/Earnings (PE) ratio of ARRIVENT BIOPHARMA INC (AVBP)?

ARRIVENT BIOPHARMA INC (AVBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.77).


What is the Short Interest ratio of ARRIVENT BIOPHARMA INC (AVBP) stock?

The outstanding short interest for ARRIVENT BIOPHARMA INC (AVBP) is 19.83% of its float. Check the ownership tab for more information on the AVBP short interest.


AVBP Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to AVBP. When comparing the yearly performance of all stocks, AVBP is one of the better performing stocks in the market, outperforming 83.36% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AVBP Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AVBP. No worries on liquidiy or solvency for AVBP as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AVBP Financial Highlights

Over the last trailing twelve months AVBP reported a non-GAAP Earnings per Share(EPS) of -3.77. The EPS decreased by -31.85% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -59.15%
ROE -62.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-171.43%
Sales Q2Q%N/A
EPS 1Y (TTM)-31.85%
Revenue 1Y (TTM)N/A

AVBP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to AVBP. The Buy consensus is the average rating of analysts ratings from 14 analysts.


Ownership
Inst Owners70.84%
Ins Owners15.2%
Short Float %19.83%
Short Ratio22.75
Analysts
Analysts87.14
Price Target40.29 (70.94%)
EPS Next Y-32.3%
Revenue Next YearN/A